In observance of World Ovarian Cancer Day, Suraksha Diagnostics hosted renowned Gynaecological Oncologist Dr. Asima Mukhopadhyay to highlight the paramount importance of early detection in improving survival rates for individuals with ovarian cancer.
Ovarian cancer ranks as the third most frequent cancer affecting women in India. Data from the Indian Council of Medical Research (ICMR) indicates that the age-adjusted incidence rate of this disease is approximately 6.8 cases per 100,000 women in India.
During a special interaction, Suraksha Diagnostics spotlighted Dr. Mukhopadhyay’s significant contributions to the field, emphasizing how her groundbreaking research and unwavering dedication are shaping the future of ovarian cancer care in India and globally. Asima has also set up a Clinical Research Program on Ovarian Cancer at Suraksha NKDA.
The central message of the discussion underscored the stark reality of ovarian cancer outcomes based on the stage of diagnosis. While early-stage (I-II) diagnoses boast significantly higher cure rates (up to 90% for stage I and 70% 5-year survival for stage II), a mere 20% of cases are currently detected at these treatable stages. Tragically, long-term survival plummets to 20% or less when the cancer spreads beyond the pelvis (stages III-IV). Computer simulations offer a promising outlook, suggesting that earlier detection of preclinical disease could lead to a substantial 10–30% improvement in survival rates and prove to be a cost-effective approach.
Dr. Mukhopadhyay, whose extensive training and PhD focused on ovarian cancer, has made a pivotal discovery identifying homologous recombination deficiency (HRD) in 50% of epithelial ovarian cancers. This finding is crucial in predicting a patient’s response to PARP inhibitors, a significant advancement in personalized treatment. Her commitment extends to establishing a vital cytoreductive surgery program and the PROVAT research group in India. Furthermore, she founded the KolGoTrg, the first Indian group within the Gynecological Cancer Intergroup, facilitating crucial participation in international clinical trials.
As a Welcome Trust Fellow and dedicated mentor for international training programs, Dr. Mukhopadhyay actively contributes to the development of global guidelines. Demonstrating her profound commitment, she also donates her PARP inhibitor royalties to support vital cancer research initiatives in India.
Suraksha Diagnostics aligns with Dr. Mukhopadhyay’s call to action, emphasizing the critical need for increased public awareness regarding the potential early warning signs of ovarian cancer and the importance of seeking timely medical attention. Proactive engagement with healthcare professionals is vital in improving outcomes for individuals facing this challenging disease.